By Ethan Covey
Regular vitamin D3 (VITD3) supplementation can increase bone density in patients with HIV receiving tenofovir disoproxil fumarate (TDF; Viread, Gilead) (Clin Infect Dis 2017 Aug 21. [Epub ahead of print]).
The data are promising for patients being treated with TDF, a common antiretroviral medication, which has been shown to decrease bone mineral density (BMD). TDF is used in HIV treatment as part of combination antiretroviral therapy (ART) and in HIV pre-exposure prophylaxis (PrEP)